Mirtazapine Sandoz (Mirtazapine)

Mirtazapine works by blocking presynaptic alpha‑2 adrenergic receptors, which increases norepinephrine release, and by antagonising 5‑HT2, 5‑HT3 and H1 receptors. This combined effect raises serotonergic and noradrenergic neurotransmission while providing antihistaminic activity, contributing to its antidepressant and anxiolytic effects.

The appropriate dose of Mirtazapine Sandoz is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of mirtazapine in pregnancy and lactation has not been definitively established. Healthcare providers weigh potential benefits against possible risks before prescribing to pregnant or nursing women, and alternative treatments may be considered when appropriate.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine differs from selective serotonin reuptake inhibitors (SSRIs) by its dual noradrenergic and serotonergic activity and strong antihistaminic effect, which often leads to sedation and weight gain. It may be preferred when patients need help with insomnia or appetite loss, whereas SSRIs are generally less sedating.

Mirtazapine Sandoz tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

The medication is taken orally, usually once daily in the evening with or without food, as directed by the prescriber. Swallow the tablet whole; do not crush or chew unless specifically instructed.

Serious risks include the potential for suicidal thoughts or behavior, especially early in treatment, agranulocytosis or severe neutropenia, and rare cases of serotonin syndrome when combined with other serotonergic drugs. Patients should be monitored closely for any sudden changes in mood or health.

Mirtazapine is contraindicated in patients with known hypersensitivity to the drug or any of its components, and it should be avoided in individuals currently taking monoamine oxidase inhibitors (MAOIs). Caution is also advised for patients with severe hepatic impairment or uncontrolled epilepsy.